Three Motley Fool contributors believe they've found such unstoppable stocks with the "it" factor to buy in August -- and ...

Donanemab, approved by the FDA in 2024 to treat Alzheimer's disease, is a monoclonal antibody directed at N-terminally ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

The combination of a recently approved blood test for detection of Alzheimer's disease combined with two medications that slow progression of the disease is drastically improving outcomes for patients ...

Get the latest business headlines including trade deals, AI in airlines, and the surprising comeback of cottage cheese. Stay ...

Eli Lilly and Company (NYSE: LLY) is one of the top low volatility healthcare stocks to buy now. On July 10, Morgan Stanley ...

Eli Lilly & Company (NYSE: LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...